Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition

被引：7
|
作者：
Marder, S. [1 ]
Laszlovszky, I. [2 ]
Szalai, E. [2 ]
Szatmari, B. [2 ]
Harsanyi, J. [2 ]
Barabassy, A. [2 ]
Debelle, M. [2 ]
Durgam, S. [3 ]
Bitter, I. [4 ]
Nemeth, G. [2 ]
机构：
[1] Univ Calif Los Angeles, Semel Inst, Sect Psychosis, Los Angeles, CA USA
[2] Gedeon Richter Plc, Med Div, Budapest, Hungary
[3] Forest Res Inst, Clin Dev, Jersey City, NJ USA
[4] Semmelweis Univ, Dept Psychiat & Psychotherapy, Budapest, Hungary
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31595-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.036
引用
收藏
页码：S550 / S550
页数：1
相关论文
共 50 条
  • [31] Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
    Demyttenaere, Koen
    Leenaerts, Nicolas
    Acsai, Karoly
    Sebe, Barbara
    Laszlovszky, Istvan
    Barabassy, Agota
    Fonticoli, Laura
    Szatmari, Balazs
    Earley, Willie
    Nemeth, Gyorgy
    Correll, Christoph U.
    EUROPEAN PSYCHIATRY, 2021, 65 (01)
  • [32] Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms
    Dirks, B.
    Eerdekens, M.
    Turkoz, I.
    Alberio, R.
    Gharabawi, G.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S162 - S162
  • [33] Cariprazine in negative symptoms of schizophrenia: post hoc analyses of a fixed-dose, placebo- and active-controlled trial
    Debelle, M.
    Faradzs-zade, S.
    Szatmari, B.
    Nagy, K.
    Nemeth, G.
    Durgam, S.
    Laszlovszky, I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S534 - S534
  • [34] Cariprazine as Monotherapy for the Treatment of Predominant Negative Symptoms of Patients with Schizophrenia: A Double-Blind, Active Comparator-Controlled Trial
    Debelle, Marc
    Kahn, Rene
    Laszlovszky, Istvan
    Szalai, Erzsebet
    Nemeth, Gyoergy
    Szatmari, Balazs
    Harsanyi, Judit
    Barabassy, Gota
    Durgam, Suresh
    Fleischhacker, Wolfgang
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S235 - S236
  • [35] Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
    Nemeth, Gyorgy
    Laszlovszky, Istvan
    Czobor, Pal
    Szalai, Erzsebet
    Szatmari, Balazs
    Harsanyi, Judit
    Barabssy, Agota
    Debelle, Marc
    Durgam, Suresh
    Bitter, Istvan
    Marder, Stephen
    Fleischhacker, W. Wolfgang
    LANCET, 2017, 389 (10074): : 1103 - 1113
  • [36] Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia
    Nemeth, Bertalan
    Bendes, Rita
    Nagy, Balazs
    Gotze, Arpad
    Koczian, Kristof
    Horvath, Margit
    Deak, Izabella
    Toth, Bernadett
    Kalo, Zoltan
    HEALTH POLICY AND TECHNOLOGY, 2019, 8 (01) : 84 - 91
  • [37] The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial
    Vieta, Eduard
    Calabrese, Joseph R.
    Whelan, Jessica
    Tohen, Mauricio
    Earley, Willie R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1635 - 1643
  • [38] Cariprazine for Negative Symptoms of Schizophrenia: Pooled Post Hoc Analysis of 2 Randomized, Double-Blind, Placebo- and Active-Controlled Trials
    Earley, Willie
    Durgam, Suresh
    Debelle, Marc
    Laszlovszky, Istvan
    Lu, Kaifeng
    Nasrallah, Henry
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S233 - S234
  • [39] Cariprazine for negative symptoms of schizophrenia: pooled post hoc analysis of 2 randomized, double-blind, placebo- and active-controlled trials
    Durgam, S.
    Earley, W.
    Lu, K.
    Nemeth, G.
    Laszlovszky, I.
    Szatmari, B.
    Edwards, J.
    Nasrallah, H. A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S552 - S552
  • [40] BAYESIAN ESTIMATION OF THE TRANSITION PROBABILITY MATRIX IN MARKOV MODELLING WITH INFORMATIVE PRIOR: AN EXAMPLE FROM THE ANALYSIS OF THE TREATMENT OF PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH CARIPRAZINE
    Voko, Z.
    Bitter, I
    Merisch, B.
    Rethelyi, J.
    Molnar, A.
    Pitter, J. G.
    Gotze, A.
    Ruzsa, V
    Koczian, K.
    Fonticoli, L.
    Lelli, F.
    Nemeth, B.
    VALUE IN HEALTH, 2019, 22 : S814 - S815
12345